GlassScriptPhysician profile
Darrell V Harris
NPI 1538191408
$466.23
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $190 · 2021: $15.32.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $137.76 | 2019-2020 | |
| Allergan, INC. | $99.57 | 2019 | |
| Abbvie INC. | $53.21 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $46.95 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.38 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $22.71 | 2020 | |
| Alfasigma USA, INC. | $20.41 | 2020 | |
| Qol Medical, LLC | $17.10 | 2020 | |
| Glaxosmithkline, LLC. | $16.82 | 2020 | |
| Braintree Laboratories, INC. | $15.32 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.